Niveau de preuve du suivi therapeutique pharmacologique du saquinavir

Gieschke, 1999, Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients, Clin Pharmacokinet, 37, 75, 10.2165/00003088-199937010-00005 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000113/WC500035084.pdf. Molla, 1996, Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat Med, 2, 760, 10.1038/nm0796-760 Le Guellec, 2009, Méthodologie pour l’évaluation du niveau de preuve du suivi thérapeutique pharmacologique, La Lettre du Pharmacologue, 23, 29 Yeni, 2010, 417 Hoetelmans, 1998, The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy, AIDS, 12, F111, 10.1097/00002030-199811000-00002 Fletcher, 2004, Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359, J Infect Dis, 189, 1176, 10.1086/382754 Marcelin, 2004, Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients, Antimicrob Agents Chemother, 48, 4687, 10.1128/AAC.48.12.4687-4692.2004 Valer, 2005, Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients, J Med Virol, 77, 460, 10.1002/jmv.20477 Mallolas, 2007, Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavirboosted saquinavir. The CIVSA Study, HIV Med, 8, 226, 10.1111/j.1468-1293.2007.00464.x http://www.hivfrenchresistance.org/2009/Algo-2009.pdf. Reijers, 2000, Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study, Aids, 14, 59, 10.1097/00002030-200001070-00007 Tam-Zaman, 2004, Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model, Pharm Res, 21, 436, 10.1023/B:PHAM.0000019296.47762.3f Eagling, 1997, Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir, Br J Clin Pharmacol, 44, 190, 10.1046/j.1365-2125.1997.00644.x Winston, 2006, Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers, AIDS, 20, 1401, 10.1097/01.aids.0000233573.41597.8a Kakuda, 2006, Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers, Pharmacotherapy, 26, 1060, 10.1592/phco.26.8.1060 Washington, 2000, The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells, Drug Metab Dispos, 28, 1058 Frohlich, 2004, Oral contraception does not alter single dose saquinavir pharmacokinetics in women, Br J Clin Pharmacol, 57, 244, 10.1111/j.1365-2125.2003.01983.x